Brodalumab, sold under the brand name Siliq in the US and Kyntheum in the EU, is a human monoclonal antibody designed for the treatment of inflammatory diseases.

[3][4][5] In February 2017, it received US FDA approval to treat moderate to severe plaque psoriasis in people who have not improved with other treatments.

The companies stated that the compound met the primary endpoint showing superior skin clearance in a Phase III trial when compared to ustekinumab and a placebo.

[9] However, in May 2015, Amgen announced that it was ending its participation in co-development of the compound because of reports of patients having "events of suicidal ideation and behavior".

[11] In July 2016, the rights to commercialize brodalumab in Europe were sold to LEO Pharma.